Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 30, 2009
Business Overview: The Company operates through two primary segments: CooperVision (CVI), which develops and markets contact lenses, and CooperSurgical (CSI), which manufactures medical devices and surgical instruments for gynecologists and obstetricians.
Key Financial Metrics
All figures in thousands, except per share data.
| Metric | Three Months Ended Apr 30, 2009 |
Three Months Ended Apr 30, 2008 |
Six Months Ended Apr 30, 2009 |
Six Months Ended Apr 30, 2008 |
|---|---|---|---|---|
| Net Sales | $260,594 | $259,248 | $511,736 | $502,020 |
| Gross Profit | $149,057 | $150,008 | $291,191 | $292,890 |
| Gross Margin | 57.2% | 57.9% | 56.9% | 58.3% |
| Operating Income | $41,207 | $28,466 | $73,988 | $48,417 |
| Net Income | $24,649 | $11,241 | $48,522 | $18,118 |
| Diluted EPS | $0.54 | $0.25 | $1.07 | $0.40 |
| Operating Cash Flow (6mo) | $68,739 (vs. $11,492 prior year) | |||
| Cash & Equivalents | $4,472 (as of Apr 30, 2009) | |||
| Total Debt | $895,593 (Short-term: $47,214; Long-term: $848,379) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 1% ($1.4M) for the quarter and 2% ($9.7M) for the six-month period compared to the prior year. On a constant currency basis, growth was 4% for both periods.
- Profitability Surge: Operating income increased 45% for the quarter and 53% for the six-month period. This was driven primarily by a 13% reduction in Selling, General, and Administrative (SG&A) expenses.
- Margin Compression: Gross margin decreased slightly from 58% to 57% due to a product mix shift toward lower-margin single-use spherical lenses and accelerated depreciation on manufacturing equipment upgrades.
- Restructuring: The Company initiated a "Critical Activity" restructuring plan in Q1 2009, incurring $3.0 million in restructuring costs during the six-month period. Total estimated costs are approximately $3.8 million.
- Legal Settlement: A $1.9 million reduction in accrued legal costs related to the Ocular Sciences acquisition was recorded as a benefit in the second quarter.
Guidance, Outlook, and Risks
- Outlook: Management remains optimistic about long-term prospects in contact lens and women's healthcare markets. However, they cite risks from the global economic downturn, credit market instability, and consumer confidence.
- Product Strategy: CVI is focusing on silicone hydrogel products (Biofinity and Avaira) to compete with market shifts. A monthly silicone hydrogel toric lens was launched in Q1 2009, with a two-week version planned for fiscal 2010.
- Liquidity: The Company believes cash on hand ($4.5M), operating cash flow, and a $650M revolving credit facility (with $150.8M available) are sufficient to fund operations, capital expenditures, and dividends for the next 12 months.
- Legal Contingencies:
- Securities Litigation: A class action lawsuit regarding the Ocular Sciences merger and financial projections remains pending with a trial date set for February 2010.
- Patent Litigation: A patent infringement suit filed by Bausch & Lomb regarding Biomedics toric lenses was settled in February 2009, resulting in a royalty-free license for the Company.
Investor Verification Checklist
- Restructuring Execution: Verify the completion of the $3.8 million restructuring plan and its impact on future SG&A expenses.
- Silicone Hydrogel Adoption: Monitor sales performance of new silicone hydrogel toric products against competitive market share gains.
- Legal Exposure: Track developments in the pending securities class action litigation regarding the Ocular Sciences merger accounting.
- Currency Hedging: Review the effectiveness of foreign exchange hedging strategies given the volatility in the Euro, Yen, and British Pound.
- Inventory Levels: Assess inventory months-on-hand (currently 7.8) to ensure alignment with demand for new product launches.